EPHX4

Across TCGA pan-cancer cohorts, EPHX4 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated EPHX4 data layer compared with 26 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher EPHX4 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated EPHX4 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, LUAD, and GBM are the cancer types where EPHX4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.577	0.302	.010	10	view →
LUAD	OS	Median	All	1.000	0.690	.031	4	view →
GBM	DFS	Median	All	0.787	0.650	.032	2	view →
LSCC	DFS	Median	III,IV	0.459	1.000	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

EPHX4–PDAC (OS)

Open the PDAC breakdown →